AG-4 has been characterized as a nicotinic agonist by binding (Ki = 26 ± 1.4 mM) and in vitro functional assays. The antinociceptive effect of AG-4 was examined in mice and rats, using the hot plate, abdominal constriction, and paw-pressure tests. In both species, AG-4 (25–150 mg per mouse icv; 100–150 mg per rat icv) produced significant antinociception which was prevented by mecamylamine (2 mg kg–1 ip) and pempidine (3 mg kg–1 i.p.), but not by atropine (5 mg kg–1 ip), naloxone (1 mg kg–1 ip) and CGP 35348 (100 mg kg–1 ip). In the antinociceptive dose range, AG-4 did not impair mice motor coordination and spontaneous motility as well as inspection activity. The present results have shown that AG-4 is a compound endowed with antinociceptive properties mediated via nicotinic activation and may be a promising beginning for new nicotinic agonists.

Antinociceptive property of the nicotinic agonist AG4 in rodents / C. GHELARDINI; N. GALEOTTI; F. GUALTIERI; C. BELLUCCI; D. MANETTI; P. BOREA; A. BARTOLINI. - In: DRUG DEVELOPMENT RESEARCH. - ISSN 0272-4391. - STAMPA. - 41:(1997), pp. 1-9. [10.1002/(SICI)1098-2299(199705)41:1<1::AID-DDR1>3.0.CO;2-M]

Antinociceptive property of the nicotinic agonist AG4 in rodents

GHELARDINI, CARLA;GALEOTTI, NICOLETTA;GUALTIERI, FULVIO;BELLUCCI, CRISTINA;MANETTI, DINA;BARTOLINI, ALESSANDRO
1997

Abstract

AG-4 has been characterized as a nicotinic agonist by binding (Ki = 26 ± 1.4 mM) and in vitro functional assays. The antinociceptive effect of AG-4 was examined in mice and rats, using the hot plate, abdominal constriction, and paw-pressure tests. In both species, AG-4 (25–150 mg per mouse icv; 100–150 mg per rat icv) produced significant antinociception which was prevented by mecamylamine (2 mg kg–1 ip) and pempidine (3 mg kg–1 i.p.), but not by atropine (5 mg kg–1 ip), naloxone (1 mg kg–1 ip) and CGP 35348 (100 mg kg–1 ip). In the antinociceptive dose range, AG-4 did not impair mice motor coordination and spontaneous motility as well as inspection activity. The present results have shown that AG-4 is a compound endowed with antinociceptive properties mediated via nicotinic activation and may be a promising beginning for new nicotinic agonists.
1997
41
1
9
C. GHELARDINI; N. GALEOTTI; F. GUALTIERI; C. BELLUCCI; D. MANETTI; P. BOREA; A. BARTOLINI
File in questo prodotto:
File Dimensione Formato  
20.DDR AG4 analgesia.pdf

accesso aperto

Tipologia: Versione finale referata (Postprint, Accepted manuscript)
Licenza: Open Access
Dimensione 207.97 kB
Formato Adobe PDF
207.97 kB Adobe PDF

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/307041
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 12
social impact